A more helpful ADJUVANT therapy.

June 29, 2017. Prelim results of the Phase III ADJUVANT trial were published this month in JCO showing a benefit with the use of post-op gefitinib (an EGFR-TKI) in EGFR-mutant non-small cell lung cancer (NSCLC) patients with completely-resected pN1-2 disease. 222 patients were randomized post-op to received gefitinib (daily pill) x 24 months versus vinorelbine/cisplatin (IV q3 weeks) x 4 cycles. With a median follow-up of 36 months, median disease-free survival was 29 months with gefitinib versus 18 with chemo (p=0.005). This is a big win for a targeted EGFR agent following big losses in 2013 and 2015, likely due to better molecular selection of patients. And if you think a pill for solid tumors is unlikely to star in any upcoming DEFINITIVE trial, breast cancer has something to say about that.


Popular Posts